Deals, Partnering

Gilead Sciences finalizes agreement with Tibotec for Prezista

Posted on 16 November 2011

Tags: , , ,

Gilead Sciences has signed a license agreement with Tibotec Pharmaceuticals for the development and commercialization of a single-tablet regimen combining Prezista (darunavir) with Gilead’s Emtriva (emtricitabine); its investigational agent GS 7340, a novel prodrug of tenofovir; and cobicistat, a pharmacoenhancer. 

Gilead will be responsible for the formulation, manufacturing, registration and, subject to regulatory approval, distribution and commercialization of the single-tablet regimen worldwide.

Tibotec will have the right to co-detail the single-tablet regimen in certain major markets.

“We are pleased to once again be partnering with Tibotec to advance and simplify HIV treatment for patients,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “This is the first time we are developing a protease inhibitor-containing single-tablet regimen, and we’re able to do that based on the small milligram size of GS 7340, which is less than one tenth of the amount of the 300 mg of tenofovir disoproxil fumarate contained in Viread and Truvada.”


See further details at Current Agreements (subscription required)

Print Friendly, PDF & Email

Leave a Reply